Tirzepatide as Compared with Semaglutide for the Treatment of Obesity

Tirzepatide, a dual GIP and GLP-1 receptor agonist, was compared with semaglutide, a GLP-1 receptor agonist, in a 72 week phase 3b trial involving adults with obesity but without type 2 diabetes. The study found that tirzepatide resulted in a significantly greater reduction in body weight (20.2%) compared to semaglutide (13.7%), as well as greater reductions in waist circumference. Both medications had similar safety profiles, with gastrointestinal adverse events being the most common.

Tirzepatide, a dual GIP and GLP-1 receptor agonist, was compared with semaglutide, a GLP-1 receptor agonist, in a 72 week phase 3b trial involving adults with obesity but without type 2 diabetes. The study found that tirzepatide resulted in a significantly greater reduction in body weight (20.2%) compared to semaglutide (13.7%), as well as greater reductions in waist circumference. Both medications had similar safety profiles, with gastrointestinal adverse events being the most common.